The United States has precisely one antibiotic recommended for the treatment of gonorrhea. That antibiotic is ceftriaxone. And according to new global data from the World Health Organization's Enhanced Gonococcal Antimicrobial Surveillance Program, resistance to that last-line treatment rose more than sixfold between 2022 and 2024 across the 13 countries whose data feed into WHO's international gonorrhea surveillance network. The data were published in late 2025 and continue to circulate in the medical literature as public health officials worldwide grapple with what they are calling a potential untreatable STI scenario.

To understand the gravity of this trajectory, it is necessary to understand the history that produced it. Gonorrhea, caused by the bacterium Neisseria gonorrhoeae, has developed resistance to virtually every antibiotic class that has ever been used to treat it. Sulfonamides, penicillin, tetracycline, fluoroquinolones such as ciprofloxacin, and cephalosporins such as cefixime have all been abandoned as reliable treatments over the past 80 years as gonorrhea evolved resistance. The current situation leaves ceftriaxone as the sole CDC-recommended option — a single point of failure in a bacterium with a well-established evolutionary track record of escaping treatment.

The Numbers That Are Alarming Public Health Officials

The EGASP data from 2022 to 2024 show the following resistance increases: ceftriaxone resistance rose from 0.8 percent to 5 percent of sampled isolates, cefixime resistance rose from 1.7 percent to 11 percent, and azithromycin resistance rose from 0.5 percent to 4 percent. And 95 percent of gonorrhea isolates now show resistance to ciprofloxacin, meaning the fluoroquinolone backup is essentially worthless.

A study published in the CDC's Emerging Infectious Diseases journal in June 2026 documents the emergence of ceftriaxone-resistant gonorrhea strains carrying the penA-60 genetic variant in Thailand during 2025, with additional resistant isolates detected in the final quarter of that year. The penA-60 variant confers high-level ceftriaxone resistance and has been observed in resistant strains circulating in multiple Asian countries. The concern is direct: once these strains reach the U.S. through international travel and sexual networks, the only domestic treatment option will no longer work.

The CDC has confirmed it has not yet identified a confirmed case in the United States of unsuccessful gonorrhea treatment due to ceftriaxone resistance. That statement acknowledges the logic of the threat clearly: failure will come eventually if resistance continues to spread globally without new treatment options being approved.

What the Pipeline Offers — and the Timeline Problem

There is genuine hope in the antimicrobial pipeline. Two investigational drugs have shown promise in late-stage trials. Zoliflodacin is a first-in-class spiropyrimidinetrione that inhibits bacterial DNA gyrase through a mechanism unrelated to existing antibiotics, making cross-resistance unlikely. Phase 3 trials published in IJID Regions in 2025 showed non-inferiority to the current ceftriaxone combination regimen. Gepotidacin, developed by GSK, showed a 92.6 percent success rate in treating gonorrhea in clinical trials, with FDA approval pending for this indication.

Neither drug is yet available. The standard timeline from completed trials to FDA approval typically spans 1 to 3 years for a priority indication. The CDC urges all clinicians to adhere strictly to current treatment guidelines, report any suspected treatment failure immediately, and perform test-of-cure for all gonorrhea patients treated at pharyngeal sites.

Gonorrhea is one of the most common bacterial STIs in the U.S., with approximately 1.6 million cases estimated annually. If left untreated, it causes pelvic inflammatory disease, ectopic pregnancy, infertility, increased HIV transmission risk, and neonatal infection. The stakes of maintaining an effective treatment are not abstract.

Read more

Frequently Asked Questions

Q: What is the current U.S. treatment for gonorrhea?

A: The CDC recommends a single intramuscular dose of 500 mg ceftriaxone as the sole recommended treatment for uncomplicated gonorrhea. It remains effective in the United States, but resistance is rising rapidly globally.

Q: How much has gonorrhea resistance to ceftriaxone increased?

A: WHO EGASP data show ceftriaxone resistance in gonorrhea isolates rose from 0.8% to 5% globally between 2022 and 2024 — more than a sixfold increase in just two years.

Q: Has anyone in the U.S. experienced a gonorrhea treatment failure yet?

A: The CDC has not confirmed a U.S. case of treatment failure due to ceftriaxone resistance as of mid-2026. However, resistant strains continue to emerge in Asia and other regions with direct travel links to the United States.

Q: Are there new gonorrhea drugs in development?

A: Yes. Zoliflodacin and gepotidacin have both completed or are completing late-stage trials showing strong efficacy against drug-resistant strains. Neither is yet FDA-approved for gonorrhea.